Equities

Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB (publ)

Actions
  • Price (SEK)0.48
  • Today's Change-0.006 / -1.23%
  • Shares traded192.15k
  • 1 Year change+26.39%
  • Beta1.0149
Data delayed at least 15 minutes, as of Nov 11 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-52.45m
  • Incorporated2014
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kancera AB0.00-53.07m199.71m5.00--2.41-----0.5955-0.59550.000.68490.00----0.00-56.73-54.82-66.40-66.21--96.28---7,249.06----0.00-------23.64------
Biosergen AB0.00-26.60m203.17m2.00--13.14-----0.286-0.2860.000.05570.00----0.00-145.58---216.30--------------0.00------32.25------
Acousort AB3.44m-19.30m203.85m----13.33--59.28-1.33-1.330.23791.020.14614.081.96---81.99-48.62-137.70-69.77-159.41-68.05-561.21-299.581.91--0.00--11.5138.81-24.01------
Active Biotech AB publ0.00-41.60m210.13m8.00--110.81-----0.0644-0.06440.000.00180.00-------284.93-57.97-1,027.16-97.83-------1,454.61----0.5758------21.54------
SenzaGen AB55.29m-20.60m222.76m32.00--2.43--4.03-0.8299-0.82992.233.110.50193.325.801,626,029.00-18.70-25.84-23.34-29.8571.6368.62-37.27-132.292.76-51.340.0443--19.3990.3211.30---21.10--
Abliva AB137.00k-102.13m242.43m6.00--2.36--1,769.54-0.0928-0.09280.00010.06380.0013--0.006222,833.33-93.81-74.59-103.87-86.98-35,826.28---74,542.34-65,958.89----0.00--341.9493.89-12.02---19.74--
Lifecare ASA15.83m-50.94m252.59m32.00--1.97--15.96-4.10-4.101.308.220.1564----502,995.00-50.29-40.00-56.16-45.26-----321.48-175.53----0.0918---40.8830.29-101.74------
Annexin Pharmaceuticals AB (publ)0.00-52.45m259.03m4.00--10.33-----0.1734-0.17340.000.04710.00----0.00-235.29-125.42-407.84-151.33------------0.00-------8.17------
Ascelia Pharma AB0.00-61.78m259.90m13.00--2.83-----1.26-1.260.000.95540.00----0.00-52.75---65.92-------------40.420.4167------16.72------
Bergenbio ASA512.42k-152.85m284.48m15.00--1.65--555.17-5.37-5.370.0184.480.0023--0.041120,840.00-67.73-66.15-85.55-78.74-----29,828.21-11,419.44----0.00---9.00-31.4336.98------
Guard Therapeutics Intrntnl AB (publ)0.00-78.82m290.16m6.00--3.66-----7.83-7.830.006.450.00-------70.61-69.56-86.38-78.62------------0.00-------0.4289------
Herantis Pharma Oyj0.00-7.10m291.05m11.00--12.3012.10---0.0146-0.01460.000.10120.00----0.00-13.93-80.46-27.32-104.37------------0.0145------103.00------
Alzinova AB300.00k-18.12m303.16m5.00--1.80--1,010.54-0.332-0.3320.00551.890.0025--0.475260,000.00-15.15-10.77-15.91-11.27-2,621.00---6,039.67-18,447.90---392.890.0076-------25.92--15.81--
Xbrane Biopharma AB199.81m-304.77m312.01m65.00--1.20--1.56-0.7304-0.97840.22660.17010.23090.43965.012,148,473.00-35.22-40.98-70.65-67.2461.87---152.53-364.400.8986-8.520.3957--314.3363.42-91.10--60.02--
Medivir AB6.93m-116.92m314.07m10.00--2.21--45.30-1.42-1.420.07351.260.0365--1.31693,300.00-61.49-28.91-81.28-34.77-1,300.04-467.42-1,686.46-675.96----0.0628--73.16-20.39-0.6275---47.96--
Data as of Nov 11 2024. Currency figures normalised to Annexin Pharmaceuticals AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 30 Sep 2024108.93k0.02%
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.